Answers are grounded in this paper and cite their sources.
Tumor-associated macrophages (TAMs) constitute a critical component of the tumor microenvironment (TME). However, the regulatory mechanisms that govern TAMs in cervical cancer (CC) remain largely unexplored. Proline-rich and Gla domain-containing protein 4 (PRRG4) has been identified as a tumor-promoting factor in various types of cancer. However, it is unclear whether PRRG4 plays a role in the progression of CC or in the regulation of TAMs. Bioinformatics analysis assessed PRRG4 expression and prognostic value in CC. PRRG4 overexpression and knockdown cells were used to evaluate M2-type TAMs (M2-TAMs) infiltration. Syngeneic mouse model validated in vivo effects, while label-free proteomics analysis elucidated mechanisms. We demonstrated that PRRG4 was highly expressed in CC tissues, and its expression positively correlated with M2-TAMs infiltration. In vitro experiments revealed that PRRG4 enhanced the viability of CC cells and promoted macrophage chemotaxis and M2‑like polarization, as evidenced by upregulation of M2 markers (CD206, ARG1, IL‑10) and downregulation of M1 markers (CD86, iNOS, TNF‑α). Syngeneic models further confirmed that PRRG4 knockdown suppressed tumor growth, reduced CD206⁺F4/80⁺ cell infiltration, and decreased PD‑L1 expression. Notably, combining PRRG4 knockdown with anti‑PD‑L1 therapy exhibited superior antitumor efficacy compared to either treatment alone. Mechanistically, we identified that PRRG4 maintains the expression level of mucin 1 (MUC1) in CC cells by antagonizing the ubiquitination and degradation of MUC1 by HECT, C2, and WW domain-containing E3 ubiquitin protein ligase 1 (HECW1), thereby facilitating CC progression. Rescue experiments confirmed that the facilitation of PRRG4 on macrophage chemotaxis and M2 polarization were reversed after MUC1 knockdown. Our findings supported a model in which PRRG4 maintained MUC1 expression by counteracting HECW1-mediated MUC1 degradation, thereby promoting M2 polarization of macrophage. These results highlighted PRRG4 as a potential immunotherapy target for CC treatment.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: